NDATOPICALCREAM
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DENAVIR (penciclovir) by Viatris is dna polymerase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENAVIR (penciclovir) is a topical nucleoside analog antiviral cream that inhibits herpesvirus DNA polymerase to reduce viral replication and duration of herpes simplex outbreaks. It is applied directly to cold sore lesions on the lips and perioral area to accelerate healing and shorten symptom duration. The drug has been a standard over-the-counter and prescription option for oral herpes management since 1996.
$0.889MPart D
LOE ApproachingMature, declining-revenue asset with minimal team headcount; career growth limited unless repositioning initiatives launched.
Mechanism of Action
DNA Polymerase Inhibitors
Pharmacologic Class:
Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Started Feb 2012
76 enrolled
Herpes Labialis
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Started Dec 2008
126 enrolled
Cold Sore
Career Relevance
DENAVIR presents a limited career opportunity for early-stage pharma professionals; the product offers exposure to mature-market dynamics, generic competition strategy, and cost-management in commoditized segments. Career growth is constrained by declining revenue, minimal clinical activity, and the LOE approaching lifecycle stage; best suited for those seeking commercial operations or market-access experience rather than innovation-focused roles.
Worked on DENAVIR at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.